Dr. Harry Stylli – Molecular Technologies Innovator
Over the course of his career, healthcare investor and entrepreneur Dr. Harry Stylli has provided executive leadership to numerous innovative companies. Dr. Harry Stylli currently serves as chairman of OncoCellMDx, a privately held diagnostic testing developer. Using technologies created internally and licensed through Harvard Medical School, the company has created non-invasive blood-based tests to evaluate a cancer’s grade and level of aggression.
Dr. Harry Stylli also leads as founding executive chair of Progenity, a company that provides genetic testing for prospective parents, as well as testing for hereditary cancer risks. The company’s suite of products includes carrier testing to screen for inherited and chromosomal disorders, as well as testing that identifies gene-specific disorders prior to intravenous fertilization (IVF) implantation. Committed to offering reliable results, Dr. Stylli has guided the creation of a laboratory that follows industry best practices for gene variant analysis.
At the start of his career, Dr. Harry Stylli served as a principal scientist and research manager for GlaxoSmithKline. As part of the firm’s advanced discovery and drug technologies division, he contributed to the evaluation of Affymax, a successful acquisition target.
Dr. Stylli went on to co-found Aurora Biosciences Corporation, which collaborated with the Cystic Fibrosis Foundation to develop the industry’s first targeted cystic fibrosis therapy. Among his many achievements at Aurora Biosciences, he was instrumental in the company’s acquisition by Vertex Pharmaceuticals. He later led CovX Pharmaceuticals, another company he founded, to inclusion in the Pfizer family of companies. Now focused on OncoCellMDx and Progenity, he continues to facilitate advancements in molecular diagnostic and therapeutic technologies.